04 Aug Next Generation COVID-19 Vaccine Trial
COVID-19 Investigational Vaccine Trial
The University of Washington is seeking volunteers for a Phase 1 COVID-19 vaccine trial. The purpose of this clinical trial is to test the safety and the body’s immune response to a new type of investigational COVID-19 vaccine called an exosome vaccine.
The study will enroll participants age 18 to 64 who received their primary COVID-19 vaccine series along with at least one booster dose.
The trial will last about 6 months and will involve 9 in-person visits. Participants will undergo a screening assessment to see whether they are eligible. Study visits will involve physical exams, blood draws, nasal swab and saliva collection, and a single vaccine injection. Participants will be asked to keep a diary of their vaccine reactions for 7-days after each injection.
Compensation:
Participants will be compensated $850 for completing the entire study.
Clinic Location:
Our clinic is located on the 11th floor of the Ninth and Jefferson Building at Harborview Medical Center and open Monday through Friday 8am to 5pm.
Participant Eligibility
To be eligible for the trial you must:
▪ Be between 18 to 64 years of age
▪ Have received their primary and booster COVID-19 vaccine
Conditions which would prevent you from participating:
▪ Previous SARS-CoV-2 infection less than 16 weeks ago
▪ Current pregnancy or breastfeeding
▪ Serious reactions to vaccines
Contact
UW Virology Research Clinic
(206) 520-4340
Additional Study Details
Full Study Title
A Phase 1 Dose Escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of STX-S for Prevention of SARS-CoV-2 Infection as a Booster Dose
Investigator(s)
Tia (Tara) Babu, MD, MS
Accepts Healthy Volunteers?
Yes
Study Site(s)
University of Washington Virology Research Clinic
908 Jefferson Street Suite 11NJ-1166
Seattle, Washington 98105
